AFTD Awards $2 Million to Advance Biomarkers Research Targeting Young-Onset Dementia

Posted on Thursday, January 26th, 2017

Doctors often rely on biomarkers – objective, easily measured biological features that indicate underlying pathology— to support accurate diagnosis and treatment efforts. Blood pressure, for example, is a widely-used biomarker for cardiovascular disease. Today, no comparable measures exist for FTD. The Association for Frontotemporal Degeneration (AFTD) aims to address these challenges with the award of $2 million to fund cutting-edge research into the discovery of FTD biomarkers.

After reviewing proposals from leading researchers worldwide, an expert panel has selected five researchers for multi-year FTD Biomarker awards. Recently released on PRNewswire, the full press release can be seen here.